source
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.Fierce Biotech · 15h ago↗ source
- Experts suggest new safety framework to boost predictability of CNS toxicity assessmentsA recent paper outlines a safety framework intended to make central nervous system (CNS) toxicity predictions more reliable during drug development. The authors argue that new approach methodologi…
- Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorder